Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in the Treatment of Patients With Acute Schizophrenia - a Multicentre, Double-Blind, Parallel Group, Randomized Study

NCT00254787 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00254787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00254787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in the Treatment of Patients With Acute Schizophrenia - a Multicentre, Double-Blind, Parallel Group, Randomized Study
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
January 31, 2006
Enrollment
30
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia